Clinical studies indicate alternate day, intermittent fasting (IMF) protocols result in meaningful weight loss in obese individuals. To further understand the mechanisms sustaining weight loss by IMF, we investigated the metabolic and neural alterations of IMF in obese mice. Male C57/BL6 mice were fed a high-fat diet (HFD; 45% fat) ad libitum for 8 weeks to promote an obese phenotype. Mice were divided into 4 groups and either maintained on ad libitum HFD (HFD), received alternate day access to HFD (IMF-HFD), switched to ad libitum low fat diet (LFD; 10% fat), or received IMF of LFD (IMF-LFD).
Introduction
Calorie restriction is the most widely prescribed and self-imposed strategy for treating excessive weight gain and obesity (1) (2) (3) . In the US, most common commercial programs for calorie reduction include reducing daily caloric intake by portion control, low calorie meals, and/or meal-replacement options (1) . Rather than reducing daily total caloric intake, intermittent fasting (IMF) has received attention as a possible approach for long-term weight loss (4) . Although varying in period of fasting (e.g., alternate day fasting or once/twice a week fasting days), IMF protocols have a similar advantage in that bouts of unrestricted eating occur following fasting periods (5, 6) . Several human studies have indicated that a short-term (i.e., 8-24 weeks) IMF protocol results in weight loss (i.e., 3-8%) in overweight or obese subjects (5-13). Weight loss occurs over several weeks because, despite overeating on refeeding days, individuals do not fully compensate for the calorie-deficit realized on the fasting days (6) . One appealing feature of IMF protocols is that dieters do not have to count calories during the bouts of unrestricted eating (4) . However, one common obstacle to the long-term adherence to IMF is intense feelings of hunger during the fasting periods (14) . These subjective feelings of hunger can be mitigated by reducing the period of fasting or providing a small meal (10) .
The influence of IMF on the hypothalamic control of energy homeostasis in obesity provides an investigative avenue from which research-based strategies to reduce hunger during fasting periods may be elucidated. In normal weight individuals, energy homeostasis, and subsequently perceived hunger, is tightly controlled through various peripheral and central signaling factors. The hypothalamus is considered one of the central regulatory regions in this regard and responds directly to peripheral signals as well as to inputs from hindbrain noradrenergic nuclei (A1 and A2) (15) . Within the hypothalamus, the arcuate nucleus (ARC), the paraventricular nucleus (PVN), and the ventromedial nucleus (VMH) are involved in energy homeostasis (16, 17) . The ARC contains orexigenic neuron populations, including neuropeptide Y (NPY)/agouti-related protein (AgRP) expressing neurons, and anorexigenic neuron populations, including proopiomelanocortin (POMC) expressing neurons (16, 17) . The PVN contains both corticotropin-releasing hormone (CRH) and thyrotropin-releasing hormone (TRH) expressing neurons. Elevations in CRH and TRH levels have been shown to decrease food intake and reduce body weight (18, 19) . Among the circulating peripheral modulators of energy homeostasis are a number of peptide hormones whose receptors can be found in these hypothalamic nuclei. One example is ghrelin, which is a gastrointestinal peptide that stimulates feeding and promotes positive energy balance (16) .
Ghrelin exerts its orexigenic response by stimulating NPY/AgRP neurons and simultaneously inhibiting POMC neurons (17) . Alternatively, the adipokine leptin functions to decrease food intake by inhibiting NPY/AgRP while stimulating POMC neurons (17) . While the actions of these peripheral and central signals are well-defined in non-obese and lean animals, the role of these signals are diminished or attenuated in states of excess weight gain and obesity.
Obesity results in distinct neural and metabolic alterations that support overconsumption and weight gain (20) (21) (22) . For instance, leptin and insulin resistance, dysregulation of hypothalamic neuropeptides, and reduced satiety signals are some of the broad physiological impairments that accompany diet-induced obesity (20, (23) (24) (25) (26) . As such, physiological changes that result in lower body weight in non-obese or lean phenotypes do not accurately represent the mechanisms of weight loss in obesity. Despite the wealth of animal studies examining how IMF improves markers for aging (27, 28) , cognitive performance (29) (30) (31) , and immune responses (32, 33) , there are no studies in obese animals to determine how IMF promotes weight loss. An understanding of the neural and metabolic alterations that promote weight loss by IMF in obese animals can provide greater insight into developing research-based modifications to IMF protocols to reduce hunger, increase long-term compliance, and enhance maintenance of weight loss.
The goal of this study was to examine the central and peripheral changes in response to IMF in a DIO model. C57 male mice at post-natal date (PND) 49 were fed a high-fat diet (HFD; 45% fat) ad libitum for 8 weeks. Following this 8-week period, mice were either maintained on ad libitum HFD, received IMF of HFD (IMF-HFD), switched to ad libitum low-fat diet (LFD; 10% fat), or received IMF of LFD (IMF-LFD). While other DIO protocols have used an extended period of high-fat feeding (> 12 weeks) (34) , the rationale for the 8 week initial high fat diet feeding study was to model the target population of overweight and obese individuals that have reported the most beneficial weight loss with intermittent fasting protocols. We hypothesized that, despite being on a high fat diet, mice fed IMF-HFD would display improved glucose metabolism, enhanced metabolic profiles, and distinct monoamine signaling in the hypothalamus comparably to LFD and IMF-LFD groups.
Materials and Methods

Animals
Male C57BL/6 mice (n=64) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). At PND 49, all were fed an ad libitum, high fat diet (HFD; 4.73 kcal/g, 45% fat, 20% protein, 35% carbohydrate; D12451) for 8 weeks. Mice were then equally divided by bodyweight and transitioned to one of four experimental groups as follows: ad libitum HFD, IMF of HFD (IMF-HFD), ad libitum low fat diet (LFD; 3.85 kcal/g, 10% fat, 20% protein, 70% carbohydrate; D12450B), or IMF of LFD (IMF-LFD).
All diets were obtained from Research Diets (New Brunswick, NJ). IMF mice were food deprived every other 24-hour period beginning at 9:00 AM (fasting day), 2 hours into the light cycle. On fasting days, all animals were weighed, food intake was recorded, and cages were changed. Mice were pair housed and maintained on a 12-hour light/dark cycle; lights on from 0700HR to 1900HR. All procedures were approved by the Institutional Animal Care and Use Committee of Rutgers University.
Body Composition and RER
Body composition was assessed using the EchoMRI 3-in-1 Body Composition Analyzer (Echo Medical Systems, Houston, TX, USA) in all mice. The Comprehensive Lab Animal Monitoring System (CLAMS) (Columbus Instruments, Columbus, OH, USA), an indirect calorimeter, was used to measure v.O2, v.CO2, and respiratory exchange ratio (RER; v.CO2/v.O2). Mice were maintained on their respective feeding protocols and housed in the system for 48 hours, beginning on a fast day for IMF-HFD and IMF-LFD mice. The second 24-hour epoch (feeding day for IMF mice) was used for analysis.
Oral Glucose and Insulin Tolerance Tests
An oral glucose tolerance test (OGTT) and an insulin tolerance test (ITT) were performed on all groups. For IMF-HFD and IMF-LFD animals, these were performed on fasting days and food was not replaced after testing. Six hours prior to the OGTT, all mice were placed in clean cages, weighed, and food deprived. At the start of the test, mice were placed in Plexiglas restrainers and a tail nick was performed to obtain a baseline glucose reading using a glucometer (AlphaTRAK 2). Immediately 
Plasma Hormones
After a 5-hour fast (fast day for IMF-HFD and IMF-LFD), animals were euthanized by decapitation. Blood was collected; a protease inhibitor, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), at 1mg/mL was added to each sample, and samples were maintained on ice until centrifugation at 3,000 rpm for 10 min at 4°C. Plasma was stored at -80°C until analysis. Insulin, ghrelin (active), and leptin were determined by multiplex assay (EMD Millipore). A radioimmunoassay was performed to determine plasma corticosterone (sensitivity: 25 ng/ml; MP Biomedicals, Santa Ana, CA, USA) levels.
Biogenic Amines
Brain samples were dissected from the anterior (containing the anterior hypothalamus and the paraventricular hypothalamus) and posterior portions of the medial hypothalamus (containing the arcuate nucleus and the ventromedial hypothalamus). Biogenic amines for each brain section were extracted and 
Tissue dissections for qPCR
Hypothalamic nuclei were micro-dissected for RNA extraction and gene expression analysis. The PVN, ARC, and VMH were cut into 1 mm coronal slices using a brain matrix (Ted Pella, Inc., Redding, CA, USA), anterior (Bregma: -0.70 to -1.34mm) and posterior (Bregma: -1.35 to -1.94mm) (36) . The brain blocks were transferred to RNAlater (Life Technologies, Inc., Grand Island, NE, USA) and stored overnight at 4°C. Samples were dissected from slices using a dissecting microscope. Dissected tissue was stored at -80°C. Total RNA was extracted from the PVN, VMH, and ARC using Ambion RNAqueousMicro Kits (Life Technologies, Inc). Total RNA was also DNase I-treated, using the extraction kits, at 37°C for 30 min to minimize any genomic DNA contamination. RNA quantity and quality were determined using a NanoDrop ND-2000 spectrophotometer (ThermoFisher, Inc., Waltham, MA, USA). All primers were designed to span exon-exon junctions and synthesized by Life Technologies using Clone Manager 5 software (Sci Ed Software, Cary, NC, USA). See Table 1 The relative mRNA expression data was analyzed using the ΔΔCT method (37, 38). The amplification protocol for all the genes was as follows: initial denaturing at 95°C for 3 min followed by 40 cycles of amplification at 94°C for 10s (denaturing), 60°C for 45s (annealing), and completed with a dissociation step for melting point analysis with 60 cycles of 95°C for 10s, 65°C to 95°C (in increments of 0.5°C) for 5s and 95°C for 5s. The reference genes used were Actb and Gapdh.
Positive and negative controls were added to each amplification run, which included a water blank.
Quantification values were generated only from samples showing a single product at the expected melting point.
Final relative quantitation was done using the comparative CT method (37, 38). The data were reported as relative mRNA expression. To determine the CT for each transcript, the threshold was consistently set at the lowest point of the exponential curve where the slope of the curve was the steepest for all plates. The relative linear quantity of target molecules was calculated using the formula 2 -ΔΔCT . All gene expression data were expressed as an n-fold difference relative to the HFD group.
Statistical Analyses
The data are presented as mean ± SEM. A two-way ANOVA or two-way ANOVA with repeated measures was performed to determine schedule, diet, and diet X schedule effects. An ANCOVA with body weight as a covariate was also performed on the RER measurements (39) . A Newman-Keuls posthoc was performed unless otherwise specified. All statistical analyses were performed using Statistica 7.1 software (StatSoft, Tulsa, OK, USA) and significance was set at α = 0.05.
Results
IMF Feeding Reduces Body Weight, Fat Mass, and Caloric Intake Comparably to a Low Fat Diet
For all groups (HFD, LFD, IMF-HFD, and IMF-LFD), we measured bodyweight, food intake, and body composition. whereas the IMF-LFD had higher lean mass than the IMF-HFD and HFD groups (p<0.05 for both), Figure 2B . with LFD group (p<0.05). For all time points, except for baseline and 15 min, the LFD was lower than the HFD group (p<0.05). In addition, the LFD group also had lower blood glucose than the IMF-HFD group at 60, 90, and 120 min (p<0.05 for all), Figure 4C . AUC analysis showed a reduction as a consequence of the intermittent schedule; IMF-HFD and IMF-LFD were lower than HFD and LFD groups, respectively (p< 0.05 for both). Also, the LFD group had lower AUC than the HFD group (p<0.05), Figure 4D .
IMF Increases RER
IMF and HFD influence terminal plasma levels of Insulin and Leptin but Not Ghrelin or Corticosterone.
Plasma levels of hormones were assessed by multiplex assay. Plasma leptin were lower in all groups compared with the HFD group (p<0.001), Figure 5B . There were no effects of diet, schedule, or diet X schedule on terminal plasma ghrelin, Figure 5C . Similarly, we did not observe any effects on terminal corticosterone (data not shown), suggesting that the IMF protocols did not induce a stress response.
Medial Hypothalamic Norepinephrine and Dopamine Increase in Response to IMF
Biogenic amines were measured in the anterior and posterior medial hypothalamus by HPLC. DA concentrations were significantly higher in the anterior medial hypothalamus of IMF-LFD animals than all other groups (p<0.001), Figure 6B (left). For 5-HT, 5-HIAA, and HVA there were no effects of diet or schedule in either hypothalamic region, Figure 6C -E.
NPY and POMC mRNA expression in the ARC and Adrenergic Receptor in the PVN of the Hypothalamus
Respond to an Intermittent Schedule of Feeding. Table 3 . For expression of Adra1a, the IMF-HFD and LFD were significantly lower than the HFD group (p<0.05). For expression of Adra1b, the LFD had lower levels than the HFD group (p<0.05), Table 3 .
Gene expressions of PVN Adra2c, Crh, Trh, and Glp1r were not significantly different between groups, Table 3 . In the VMH, expressions of Glp1r, Adra1a, Adra1b, Adra2b, and Adra2c showed no significant effects of either diet or schedule of the diet, Table 4 .
Discussion
Several clinical studies have indicated that intermittent fasting is an effective weight loss treatment for some obese and overweight populations (7, 9, 11, 40) . However, there have not been any preclinical studies examining the effects of this diet strategy in animal models of obesity. The intermittent fasting protocol used in our study was an alternate day fasting regimen with repeated 24-hour intervals of food deprivation followed by 24-hour ad libitum food access. Our study sought to further understand the neural and metabolic consequences of an intermittent fasting protocol in adult male DIO mice. In particular, our study promoted an obese phenotype by exposing mice to ad libitum high-fat feeding for 8
weeks before beginning the intermittent fasting protocol or low fat/low calorie diet switch (LFD). One group of mice was maintained on the high-fat diet throughout the study (HFD; 12 weeks total), which was the control group in these experiments. Indeed, most intermittent fasting protocols in humans have been validated in overweight, class I obese (BMI < 34.9), or class II obese (BMI < 39.9) individuals (7-10, 40).
However, most of the subjects in these studies were either overweight or class I obese (40) .
In order to uncover the neural and metabolic changes that promote weight loss by intermittent fasting, our measurements were taken after significant body weight loss was achieved. This was achieved at the 4 week time point in the present set of experiments. At 4 weeks, body weights were significantly lower in IMF-HFD (~13 % reduction) and IMF-LFD (~18% reduction) groups compared with the HFD group. It is important to note that all three groups (IMF-HFD, LFD, and IMF-LFD) consumed statistically similar cumulative caloric intakes over the 4-week period (~15-20% reduction compared with the HFD group). While the study did not have a pair-fed control groups, there was complete overlap in cumulative caloric intakes between the IMF-HFD and LFD diet groups (i.e., calorie-matched). As a result, there was a reduction in fat mass in all groups compared with the HFD group. This was also reflected in reduced terminal plasma leptin levels by approximately 65% in all groups compared with the HFD group. Thus, it appears that IMF of a HFD is similarly effective at reducing caloric intake and, therefore, fat accumulation, as a low fat/low calorie diet.
One interesting finding in our study was that the IMF-LFD had higher lean mass than the HFD and IMF-HFD groups. While the cause for this increase in lean mass is unknown, retention of lean mass has been reported in humans undergoing a modified intermittent fasting protocol for 7 weeks (6). In a study by Klempel and colleagues (6), overweight or obese subjects (BMI 30-39.9; n= 32 completers)
were randomly assigned to receive a high-fat diet (45% fat) or lower fat diet (25% fat). To reduce feelings of hunger, subjects were able to consume 25% of their energy needs on fast days. At the completion of the study, subjects in either the high-fat or low-fat intermittent fasting regimen lost weight from baseline (~ 4.5%), but there was no difference in amount of weight loss or body composition between diets (6).
The retention (or elevation in lean mass) is in contrast to the findings observed by Chausse and colleagues (2014) in non-obese male Sprague Dawley rats exposed to an alternate fasting protocol for 3 weeks (41).
In that study, intermittent fasting produced a reduction in epididymal fat mass, it also resulted in a reduction of soleus and plantaris muscle mass compared with ad libitum feeding of the same AIN-93 diet (13.8% protein, 76% carbohydrates, 10.2 % fat).
Chausse and colleagues (2014) also found similar relative RER levels between ad libitium and intermittent fasting (on fed days) rats (41), whereas our findings indicate an increase in RER on fed days with intermittent fasting with respect to diet (i.e., IMF-HFD was increased relative to HFD and IMF-LFD was increased relative LFD). Besides the difference in rodent species and diets, one prominent difference in the design of our study and that of Chausse et al., (2014) was that our mice were placed on high-fat diet for 8 weeks prior to the intermittent fasting regimen. Future studies will be designed to determine if the metabolic changes associated with DIO promote the retention of lean mass during an intermittent fasting regimen.
Another major finding of the present study was that oral glucose tolerance was slightly improved with an intermittent fasting of high-fat diet. Although there was not a difference in AUC, 15 min following the oral glucose load, blood glucose levels were lower in the IMF-HFD and LFD groups.
Possibly related to the retention in lean mass, the IMF-LFD had lower glucose levels, over time and when expressed as AUC, following the oral glucose load. Improvements with intermittent fasting and a LFD were also observed in the insulin tolerance tests. Notably, terminal plasma insulin levels were reduced by approximately 45% in all groups compared with the obese HFD group. Improvements in insulin levels have been noted with long-term intermittent fasting protocols in overweight and obese women (5) . In a 24-week study, overweight or obese women (30 ± 5 kg/m2 BMI) were randomly divided into either a continuous calorie restriction of 25% or an IMF protocol of 2 consecutive fasting days (75% calorie restriction) per week. At 6 months, weight reduction was 7% in both groups, but the IMF subjects had significantly improved fasting insulin (5.2 vs. 6.3 µU/ml) and lower HOMA scores (1.1 vs. 1.3 µU/mmd/L) than continuously calorie restricted subjects (5) . Reductions in plasma levels of insulin levels also have been noted with intermittent fasting protocols in non-obese rodents (27-29, 33, 42) . Therefore, combination of intermittent fasting regimen with a lower fat diet could be beneficial for the glucose homeostatic impairments associated with obesity. Because we did not measure free fatty acids, lipoproteins, or markers for fat oxidation, it is unclear how an intermittent fasting regimen with a lower fat diet improves obesity-related impairments associated with obesity.
The increase in hypothalamic norepinephrine (NE) content as a consequence of the intermittent fasting schedule is another major finding of our study. and Npy gene expression were performed on regions rather than distinct nuclei, future experiments will use targeted more mechanistic approaches to uncover the role of the NE and NPY in the weight loss and glucose regulatory alterations that accompany intermittent fasting.
Another finding of our study was that dopamine (DA) content in the posterior region of the medial hypothalamus was increased in the IMF-LFD compared with the IMF-HFD and LFD groups. In a study by Martin and colleagues, regional monoamine content was measured after 6 month on different dietary feeding protocols, including intermittent fasting, in male and female non-obese rats (29) . Although hypothalamic regions were not examined, there were differences in the catecholamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the cerebellum of male and female rats exposed to the intermittent fasting schedule (29) . Female rats exposed to a 40% caloric restriction for 6 months had increased performance in behavioral cognitive task which was accompanied by a decrease in DA and increase in serotonin content in the hippocampus compared with ad libitum fed rats (29) . Thus, the significance of the increase in DA in the posterior medial hypothalamus in DIO mice exposed to the IMF-LFD schedule is unclear. In addition, another limitation of our methods is that measurements of biogenic amine tissue content do not provide an accurate index of biogenic amine turnover or steady-state concentrations (52).
An obstacle for intermittent fasting regimens is the feelings of hunger that accompany prolonged bouts of food deprivation (14) . Ghrelin is a gastrointestinal hormone that is elevated during period of fasting and associated with subjective feeding of hunger in non-obese adults (53) . Fasting increases GHSR in the hypothalamus (54) while diet-induced obesity via a high-fat diet has been shown to induce ghrelin resistance in arcuate NPY/AgRP neurons (55) . In addition, though the actions of peripheral ghrelin are thought to be primarily through the afferent vagal nerve to the hindbrain (56), there exist ghrelin-containing cells within the hypothalamus and specifically the ARC (57, 58) . Interestingly, hypothalamic ghrelin release decreases in glucoprivic states, such as with fasting or 2DG administration, whereas the opposite effect is observed with peripheral ghrelin release (59) . In our study, terminal ghrelin levels were not elevated, but the relative gene expression of the ghrelin receptor, Ghsr, was increased in the ARC of animals placed on the intermittent feeding schedules (i.e., IMF-HFD and IMF-LFD). Future work is needed to understand the feed-forward increase in Ghsr gene expression, subjective feelings of hunger, and the weight loss associated with intermittent fasting protocols.
Because our study design used pair-housed mice, one limitation of our findings is that dietspecific calorie restricted groups were not included in our study. Information gathered from a restricted access to diet, but not exposed to prolonged periods of food deprivation, would provide insight into whether fasting has benefits over simple calorie restriction. As it stands, our studies do not resolve the ongoing debate as to whether intermittent fasting provides an added benefit beyond daily caloric restriction (4) . Keeping in mind the limitation of extrapolating animal studies and fasting periods to clinical practice, these studies do provide a starting point for research-based human studies to examine the efficacy of long-term intermittent fasting regimens for weight loss in certain populations of overweight or obese individuals. 
